まとめ
コレスティラミン樹脂は2人の患者の下痢と偽膜性大腸炎を効果的に治療しました. これらの症状はリンコマイシンとクリンダマイシン療法と関連しており,コレステラミンは迅速な症状緩和をもたらしました.
科学分野:
- 胃腸内科 胃腸内科
- 感染症 感染症は感染症です.
- 薬理学 薬理学とは
背景:
- 抗生物質関連下痢と擬膜性大腸炎は,臨床的に重要な懸念事項である.
- リンコマイシン塩化水素モノヒドレートとクリンダミシンリン酸塩は,胃腸の副作用が知られている,一般的に使用される抗生物質です.
研究 の 目的:
- 2人の患者で下痢と偽膜性大腸炎の治療に成功したことを報告する.
- これらの抗生物質による合併症の管理におけるコレステラミン樹脂の有効性を評価する.
主な方法:
- 重度の下痢と偽膜性大腸炎を呈した患者の2件の症例が特定されました.
- 両方の患者にコレステラミン樹脂を用いた治療を開始した.
主要な成果:
- 両方の患者はコレステラミン投与後,胃腸症状の迅速かつ完全な寛解を示した.
- コレスティラミン樹脂の治療中に有害事象は報告されていません.
結論:
- コレスタイラミン樹脂は,リンコマイシンとクリンダマイシンに関連した下痢および偽膜性大腸炎の管理のための安全で効果的な治療法であるようです.
- このケースレポートは,特定の抗生物質による胃腸障害の臨床管理におけるコレステラミンの潜在的な役割を示唆しています.
関連する概念動画
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...